BR9916495A - Uso de 5ht3-receptor-antagonistas - Google Patents
Uso de 5ht3-receptor-antagonistasInfo
- Publication number
- BR9916495A BR9916495A BR9916495-7A BR9916495A BR9916495A BR 9916495 A BR9916495 A BR 9916495A BR 9916495 A BR9916495 A BR 9916495A BR 9916495 A BR9916495 A BR 9916495A
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- receptor
- cfs
- suggested
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Patente de Invenção: <B>"USO DE 5HT~ 3~-RECEPTOR-ANTAGONISTAS"<D>. é sugerido o uso de 5HT~ 3~-receptor-antagonistas para a fabricação de uma droga para o tratamento de CFS (Síndrome da Fadiga Crónica).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19859406 | 1998-12-22 | ||
PCT/DE1999/004071 WO2000037073A1 (de) | 1998-12-22 | 1999-12-22 | Verwendung von 5ht3-rezeptor-antagonisten zur therapie des chronischen müdigkeitssyndrom |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9916495A true BR9916495A (pt) | 2001-09-04 |
Family
ID=7892223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9916495-7A BR9916495A (pt) | 1998-12-22 | 1999-12-22 | Uso de 5ht3-receptor-antagonistas |
Country Status (9)
Country | Link |
---|---|
US (2) | US6740672B1 (pt) |
EP (1) | EP1140076A1 (pt) |
JP (1) | JP2002532549A (pt) |
CN (1) | CN1161118C (pt) |
AU (1) | AU759250B2 (pt) |
BR (1) | BR9916495A (pt) |
CA (1) | CA2356246A1 (pt) |
MX (1) | MXPA01006319A (pt) |
WO (1) | WO2000037073A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004014429A1 (ja) * | 2002-08-09 | 2004-02-19 | Mitsubishi Pharma Corporation | 精神疾患発症脆弱性制御剤 |
CA2597962A1 (en) | 2005-02-17 | 2006-08-24 | Amr Technology, Inc. | Benzoxazole carboxamides for treating cinv and ibs-d |
MX2012000572A (es) | 2009-07-14 | 2012-05-08 | Albany Molecular Res Inc | Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. |
KR101778439B1 (ko) | 2015-04-27 | 2017-09-14 | 울산대학교 산학협력단 | 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
EP0591434A4 (en) * | 1991-06-26 | 1994-09-14 | Sepracor Inc | Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron |
GB9412995D0 (en) * | 1994-06-28 | 1994-10-26 | Prendergast Kenneth F | Safety enhancing pharmaceutical compositions of an active indazole |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
-
1999
- 1999-12-22 BR BR9916495-7A patent/BR9916495A/pt not_active IP Right Cessation
- 1999-12-22 JP JP2000589184A patent/JP2002532549A/ja not_active Withdrawn
- 1999-12-22 CA CA002356246A patent/CA2356246A1/en not_active Abandoned
- 1999-12-22 MX MXPA01006319A patent/MXPA01006319A/es unknown
- 1999-12-22 AU AU24285/00A patent/AU759250B2/en not_active Ceased
- 1999-12-22 EP EP99967889A patent/EP1140076A1/de not_active Withdrawn
- 1999-12-22 CN CNB998158445A patent/CN1161118C/zh not_active Expired - Fee Related
- 1999-12-22 US US09/868,972 patent/US6740672B1/en not_active Expired - Fee Related
- 1999-12-22 WO PCT/DE1999/004071 patent/WO2000037073A1/de not_active Application Discontinuation
-
2004
- 2004-04-30 US US10/837,370 patent/US20040204467A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000037073A1 (de) | 2000-06-29 |
CN1161118C (zh) | 2004-08-11 |
US20040204467A1 (en) | 2004-10-14 |
CA2356246A1 (en) | 2000-06-29 |
AU759250B2 (en) | 2003-04-10 |
MXPA01006319A (es) | 2003-06-06 |
CN1333684A (zh) | 2002-01-30 |
AU2428500A (en) | 2000-07-12 |
EP1140076A1 (de) | 2001-10-10 |
US6740672B1 (en) | 2004-05-25 |
JP2002532549A (ja) | 2002-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0213358A (pt) | Uso de flibanserina | |
BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
BR9713147A (pt) | Benzamidoaldeìdo, uso do mesmo, benzamida, e, preparação medicamentosa para administração oral, parenteral ou intraperitoneal. | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
BRPI0013478B8 (pt) | medicamento compreendendo inibidor pde e uso de roflumilast | |
BR9808227A (pt) | Preparação medicinal contendo gás inerte lipofìlico | |
BR9914978A (pt) | Estabilização de produtos de cuidados do corpo e domésticos | |
BR9711194A (pt) | Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer. | |
DK0801564T3 (da) | Anvendelse af nebivolol som et antiatherogent middel | |
BR0109131A (pt) | Fator viii modificado | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
BR0102040A (pt) | Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida | |
AR025883A1 (es) | Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos | |
ATE390133T1 (de) | Gabapentinanaloga für schlafstörungen | |
BR9807655A (pt) | Uso de inibidores de lipase gastrintestinal. | |
BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
BR0107493A (pt) | Substâncias para uso no tratamento de psorìase | |
BR9813996A (pt) | 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio | |
BR9810337A (pt) | Utilização de um antagonista especìfico dos receptores 5ht2 para a preparação de medicamentos úteis no tratamento da sìndrome de apnéia do sono | |
BRPI0408889A (pt) | uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas | |
AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6O E 7O ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007. |